Exenatide Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Exenatide dosing: protocols, safety, and where to buy.
Dose Range
5 to 10 mcg twice daily (Byetta, immediate-release) or 2000 mcg (2 mg) once weekly (Bydureon, extended-release)
Frequency
Twice daily before meals (immediate-release) or once weekly (extended-release)
Cycle Length
Not cycled. GLP-1 receptor agonists are used as continuous, long-term therapy for as long as they remain clinically beneficial. There is no on/off cycling protocol.
Half-Life
Immediate-release (Byetta): terminal half-life about 2.4 hours, cleared mainly by the kidneys. Extended-release (Bydureon): the same peptide is released slowly from biodegradable microspheres over roughly 10 weeks, reaching steady-state plasma levels by about 6 to 7 weeks.
Dosage Calculator
Calculate exact dosing for Exenatide.
Dosing Protocols
Reference regimen - immediate-release (Byetta), starting dose. 5 mcg injected subcutaneously twice daily, within 60 minutes before the morning and evening meals (never after a meal). This starter dose is used for roughly the first 4 weeks to let the gut adjust and limit nausea. Rotate injection sites (abdomen, thigh, upper arm). This is a prescription regimen that should only be run under medical supervision; it is presented here for educational, research-use-only reference, not as medical advice.
Reference regimen - immediate-release (Byetta), maintenance dose. After about 4 weeks at 5 mcg, the label dose increases to 10 mcg subcutaneously twice daily, again within 60 minutes before the morning and evening meals. Most of the glucose-lowering and appetite effect is seen at this dose. When exenatide is combined with a sulfonylurea or insulin, the dose of those agents is usually reduced first to limit hypoglycemia. Prescription-only; medical supervision required.
Reference regimen - extended-release (Bydureon / Bydureon BCise), once weekly. 2 mg (2000 mcg) injected subcutaneously once every 7 days, at any time of day, with or without food, on the same day each week. Steady-state levels build over about 6 to 7 weeks, so the full effect is delayed. The weekly formulation produced slightly greater HbA1c reductions than twice-daily dosing in the DURATION-1 trial [PMID:18782641], with a lower injection burden, at the cost of more injection-site nodules. Prescription-only; medical supervision required.
Side Effects & Safety
Contraindications
Do not use with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (boxed warning for the extended-release form). Contraindicated after any prior serious hypersensitivity reaction to exenatide. Not recommended in severe renal impairment (creatinine clearance under 30 mL/min) or end-stage renal disease, because clearance is kidney-dependent. Use caution or avoid with a history of pancreatitis, severe gastrointestinal disease, or gastroparesis. Exenatide does not treat type 1 diabetes or diabetic ketoacidosis. It is not recommended in pregnancy or breastfeeding, and it is not FDA-approved for weight loss or for use in people without diabetes.
Frequently Asked Questions
What is the recommended Exenatide dosage?
The typical dose range for Exenatide is 5 to 10 mcg twice daily (Byetta, immediate-release) or 2000 mcg (2 mg) once weekly (Bydureon, extended-release). It is usually administered Twice daily before meals (immediate-release) or once weekly (extended-release). Always start with the lowest effective dose.
How often should I take Exenatide?
Twice daily before meals (immediate-release) or once weekly (extended-release)
Does Exenatide need to be cycled?
Yes, typical cycle length is Not cycled. GLP-1 receptor agonists are used as continuous, long-term therapy for as long as they remain clinically beneficial. There is no on/off cycling protocol..
What are Exenatide side effects?
Gastrointestinal effects are by far the most common: nausea (reported in roughly 40 to 57 percent of patients on the twice-daily form, usually worst early and fading over weeks), vomiting, diarrhea, constipation, and dyspepsia. Reduced appetite is expected. Other reported effects include headache, dizziness, jitteriness, and injection-site reactions - small subcutaneous nodules are especially common with the extended-release (weekly) formulation. Hypoglycemia is uncommon with exenatide alone but rises when it is combined with a sulfonylurea or insulin. Less common but serious concerns include acute pancreatitis, gallbladder disease, and acute kidney injury (usually linked to dehydration from nausea or vomiting). The extended-release product carries a boxed warning for thyroid C-cell tumors based on rodent studies.
Where can I buy Exenatide?
Visit our vendor directory to compare the vendors we track and their Trust Scores.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.